← Back to Search

PrEP Awareness Program for HIV Prevention in Black Women

N/A

Waitlist Available

Led By Amy Corneli, MPH, PhD

Research Sponsored by Duke University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 12 months

Awards & highlights

Study Summary

This trial aims to measure the effectiveness of a program that encourages conversations about PrEP for Black women. It will use interviews, reviews, records and social media metrics.

Who is the study for?

This trial is for LSU GYN residents and Black cisgender women who meet the CDC guidelines for PrEP, a medication that helps prevent HIV. It's designed to evaluate an initiative aimed at increasing PrEP use among these women in New Orleans.Check my eligibility

What is being tested?

The 'Start the Conversation' Initiative includes training for GYN residents and a social media campaign, both aiming to boost awareness and uptake of PrEP among eligible Black cisgender women to prevent HIV infection.See study design

What are the potential side effects?

Since this study focuses on implementation rather than drug effects, it doesn't directly involve side effects from interventions. However, general side effects of PrEP can include nausea, headaches, stomach pain, and weight loss.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Comparison of the difference in patient numbers at the LSU GYN clinic during pre-implementation and the two implementation period phases with the difference in patient numbers during the same time frame at the Tulane GYN clinic.

Number of patients seen at LSU GYN clinic & UMC PrEP clinic combined compared to the number of patients seen at Tulane GYN & PrEP clinics combined

Total number of women overall and number of Black cisgender women initiating PrEP at the LSU GYN clinic during the pre-implementation period compared to during the two implementation period phases.

+1 more

Secondary outcome measures

Number of appointments made through the LDH navigator

Number of contacts with the LDH navigator

Proportion of PrEP-eligible women overall and Black cisgender women initiating PrEP at the LSU GYN clinic across the two implementation time periods. care model plus social media company.

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Start the Conversation PackageExperimental Treatment2 Interventions

The pre-intervention phase will last for 4 months (months 1-4). The only study activity during the pre-intervention phase is the collection of routine PrEP uptake data to establish a baseline for PrEP prescribing at the GYN residency clinics and local PrEP clinics. The implementation of the combined-care model at the LSU GYN residency clinic at UMCNO for 10 months (months 5-14). Then we will add implementation of the social media campaign in the NOLA area for 4 months (months 5-18); implementation of the combined-care model at LSU GYN residency clinic at UMCNO will continue. The layered approach allows for an opportunity to assess the effect of the combined-care model, and subsequently, to what extent the social media campaign additionally engages Black women and builds demand for PrEP.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Social Media Campaign

2022

N/A

~57910

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor

2,358 Previous Clinical Trials

3,419,655 Total Patients Enrolled

Louisiana State University Health Sciences Center in New OrleansOTHER

114 Previous Clinical Trials

43,787 Total Patients Enrolled

National Institute of Mental Health (NIMH)NIH

2,782 Previous Clinical Trials

2,688,693 Total Patients Enrolled

Media Library

Start the Conversation Package Clinical Trial Eligibility Overview. Trial Name: NCT05909176 — N/A

Human Immunodeficiency Virus Infection Research Study Groups: Start the Conversation Package

Human Immunodeficiency Virus Infection Clinical Trial 2023: Start the Conversation Package Highlights & Side Effects. Trial Name: NCT05909176 — N/A

Start the Conversation Package 2023 Treatment Timeline for Medical Study. Trial Name: NCT05909176 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment of participants still open for this research project?

"As per the clinicaltrials.gov information, this medical trial is not enrolling at present. The study was first listed on May 5th 2023 and revised on June 8th of the same year; however, there are presently 475 other studies actively searching for patients to participate in their trials."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Start the Conversation: Evaluating Implementation of a Multi-level PrEP Initiative for Black Cisgender Women in Nola

Meredith Clement 2023. "Start the Conversation: Evaluating Implementation of a Multi-level PrEP Initiative for Black Cisgender Women in Nola". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05909176.